As of 2025-11-07, the EV/EBITDA ratio of Nurix Therapeutics Inc (NRIX) is -3.36. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NRIX's latest enterprise value is 884.10 mil USD. NRIX's TTM EBITDA according to its financial statements is -263.42 mil USD. Dividing these 2 quantities gives us the above NRIX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.0x - 15.8x | 15.4x |
| Forward P/E multiples | 21.3x - 51.3x | 36.3x |
| Fair Price | (71.96) - (53.12) | (87.55) |
| Upside | -674.8% - -524.2% | -799.3% |
| Date | EV/EBITDA |
| 2025-11-05 | -3.34 |
| 2025-11-04 | -3.28 |
| 2025-11-03 | -3.39 |
| 2025-10-31 | -3.48 |
| 2025-10-30 | -3.43 |
| 2025-10-29 | -3.12 |
| 2025-10-28 | -3.18 |
| 2025-10-27 | -3.20 |
| 2025-10-24 | -2.94 |
| 2025-10-23 | -2.74 |
| 2025-10-22 | -2.80 |
| 2025-10-21 | -2.74 |
| 2025-10-20 | -2.73 |
| 2025-10-17 | -2.57 |
| 2025-10-16 | -2.63 |
| 2025-10-15 | -2.72 |
| 2025-10-14 | -2.38 |
| 2025-10-13 | -2.54 |
| 2025-10-10 | -2.55 |
| 2025-10-09 | -2.87 |
| 2025-10-08 | -2.61 |
| 2025-10-07 | -2.57 |
| 2025-10-06 | -2.61 |
| 2025-10-03 | -2.44 |
| 2025-10-02 | -2.35 |
| 2025-10-01 | -2.45 |
| 2025-09-30 | -2.40 |
| 2025-09-29 | -2.41 |
| 2025-09-26 | -2.31 |
| 2025-09-25 | -2.13 |
| 2025-09-24 | -2.24 |
| 2025-09-23 | -2.11 |
| 2025-09-22 | -2.16 |
| 2025-09-19 | -2.17 |
| 2025-09-18 | -2.32 |
| 2025-09-17 | -2.20 |
| 2025-09-16 | -2.17 |
| 2025-09-15 | -2.23 |
| 2025-09-12 | -2.34 |
| 2025-09-11 | -2.39 |
| 2025-09-10 | -2.31 |
| 2025-09-09 | -2.39 |
| 2025-09-08 | -2.53 |
| 2025-09-05 | -2.59 |
| 2025-09-04 | -2.36 |
| 2025-09-03 | -2.46 |
| 2025-09-02 | -2.36 |
| 2025-08-29 | -2.43 |
| 2025-08-28 | -2.45 |
| 2025-08-27 | -2.49 |